Cargo Therapeutics (NASDAQ:CRGX) Stock

CARGO THERAPEUTICS INC

Cargo Therapeutics

Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.

UBS analyst Geoff Haire maintains Linde (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIN#NASDAQ">LIN</a>) with a Neutral and raises the price target from $485 to $504.

News

Price Target

Analyst Ratings

UBS Maintains Neutral on Linde, Raises Price Target to $504

WIIM

Thermo Fisher Scientific shares are trading lower after UBS downgraded the stock from Buy to Neutral and lowered its price target from $500 to $460.

MNST

Monster Beverage shares are trading lower after Redburn Atlantic downgraded the stock from Buy to Neutral and lowered its price target from $63 to $60.

UBS analyst Cody Ross maintains Ingredion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INGR#NYSE">INGR</a>) with a Neutral and raises the price target from $149 to $151.

INGR

UBS Maintains Neutral on Ingredion, Raises Price Target to $151

UBS analyst David Vogt maintains IBM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) with a Sell and raises the price target from $170 to $195.

UBS Maintains Sell on IBM, Raises Price Target to $195

UBS analyst Brian Meredith maintains The Hartford Insurance Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIG#NYSE">HIG</a>) with a Buy and raises the price target from $142 to $145.

UBS Maintains Buy on The Hartford Insurance Gr, Raises Price Target to $145

UBS analyst Joshua Spector maintains Corning (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLW#NYSE">GLW</a>) with a Neutral and raises the price target from $54 to $57.

UBS Maintains Neutral on Corning, Raises Price Target to $57

UBS analyst Joshua Spector maintains FMC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMC#NYSE">FMC</a>) with a Neutral and raises the price target from $41 to $45.

UBS Maintains Neutral on FMC, Raises Price Target to $45

B of A Securities analyst George Staphos maintains Crown Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCK#NYSE">CCK</a>) with a Buy and raises the price target from $110 to $117.

B of A Securities Maintains Buy on Crown Holdings, Raises Price Target to $117

UBS analyst Joshua Spector maintains Element Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESI#NYSE">ESI</a>) with a Buy and raises the price target from $25 to $29.

UBS Maintains Buy on Element Solutions, Raises Price Target to $29

Viper Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNOM#NASDAQ">VNOM</a>) has outperformed the market over the past 5 years by 15.74% on an annualized basis producing an average annual return of 30.08%. Currently, Viper Energy has a market capitalization of $4.93 billion. 
Buying $100 In VNOM: If an investor had bought $100 of VNOM stock 5 years ago, it would be worth $389.87 today based on a price of $37.64 for VNOM at the time of writing.
<h3>Viper Energy's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752072327_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

VNOM

Here's How Much You Would Have Made Owning Viper Energy Stock In The Last 5 Years

UBS analyst Joshua Spector maintains Ecolab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>) with a Neutral and raises the price target from $271 to $288.

UBS Maintains Neutral on Ecolab, Raises Price Target to $288

<a href="https://x.com/lindayaX/status/1942957094811951197" title="https://x.com/lindayaX/status/1942957094811951197">https://x.com/lindayaX/status/1942957094811951197</a>

Management

X CEO Linda Yaccarino Writes "After two incredible years, I've decided to step down as CEO of X. ...."

B of A Securities analyst George Staphos maintains Graphic Packaging Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPK#NYSE">GPK</a>) with a Buy and lowers the price target from $31 to $28.

B of A Securities Maintains Buy on Graphic Packaging Holding, Lowers Price Target to $28

CLDI

Calidi Biotherapeutics Shares Halted On Circuit Breaker To The Downside, Stock Now Up 195.5%

B of A Securities analyst George Staphos maintains Avery Dennison (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVY#NYSE">AVY</a>) with a Buy and raises the price target from $195 to $208.

B of A Securities Maintains Buy on Avery Dennison, Raises Price Target to $208

UBS analyst Joshua Spector maintains DuPont de Nemours (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) with a Buy and raises the price target from $85 to $87.

UBS Maintains Buy on DuPont de Nemours, Raises Price Target to $87

UBS analyst Joshua Spector maintains Corteva (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTVA#NYSE">CTVA</a>) with a Buy and raises the price target from $76 to $90.

CTVA

UBS Maintains Buy on Corteva, Raises Price Target to $90

UBS analyst Joshua Spector maintains Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) with a Neutral and raises the price target from $51 to $66.

UBS Maintains Neutral on Celanese, Raises Price Target to $66

NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) shares continued their meteoric rise on Wednesday, as the stock surged to a new all-time high and propelled its market capitalization beyond the historic $4 trillion threshold. Here&#8217;s what investors <a href="https://www.benzinga.com/quote/NVDA/news">need to know</a>.
What To Know: Wednesday&#8217;s rally follows a pivotal announcement that has quelled market uncertainty. On Monday, key customer OpenAI <a href="https://www.benzinga.com/markets/equities/25/07/46290622/openai-sticks-with-nvidia-chatgpt-maker-says-no-plans-to-use-googles-ai-chips-at-scale">publicly reaffirmed</a> its commitment to using Nvidia&#8217;s AI chips at scale, dispelling rumors of a potential shift to Google's competing hardware. 
This endorsement helps solidify Nvidia&#8217;s position as the foundational hardware provider for the world&#8217;s leading AI models. Further <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46253485/nvidia-stock-hits-new-all-time-highs-whats-driving-the-record-breaking-run">bolstering sentiment</a> is the passing of the "Big Beautiful Bill," which aims to increase the U.S. semiconductor investment tax credit, and news that key supplier TSMC is accelerating its American expansion, shoring up Nvidia&#8217;s supply chain.
Despite the bullish momentum, the company is still navigating persistent geopolitical headwinds. The U.S. government is <a href="https://www.benzinga.com/markets/asia/25/07/46266218/us-plans-to-restrict-ai-chip-exports-to-malaysia-thailand-to-curb-diversion-to-china">reportedly drafting</a> new rules to restrict AI chip exports to China through intermediary countries like Malaysia and Thailand, expanding on existing controls that have previously impacted Nvidia&#8217;s revenue projections.
Last week, investor anticipation was <a href="https://www.benzinga.com/markets/tech/25/07/46261478/nvidias-4t-countdown-will-next-weeks-chart-print-a-trillion-dollar-breakout">fueled</a> by a Morgan Stanley note citing &#8220;very strong demand for all Blackwell form factors&#8221; and new partnerships in Europe offsetting weaker sales in China. 
The optimism was compounded as competitive threats from rivals appeared to fade, with reports of Microsoft facing delays in its own chip development and OpenAI confirming it would not scale back its use of Nvidia hardware. 
Despite its astronomical rise, Nvidia&#8217;s valuation remains reasonable, with a forward P/E ratio <a href="https://www.benzinga.com/markets/tech/25/07/46261478/nvidias-4t-countdown-will-next-weeks-chart-print-a-trillion-dollar-breakout">comparable to industry peers</a>.
Benzinga Edge Rankings: Based on the provided <a href="http://benzinga.grsm.io/register174">Benzinga Edge</a> rankings, NVDA shows exceptional strength in Growth with a score of 98.59, and very strong Momentum at 76.28. These high scores suggest the stock has demonstrated powerful upward price movement and is backed by significant growth indicators.
However, its Value score is notably low at 6.94, which indicates that the stock may be considered overvalued compared to its peers or intrinsic worth.
Price Action: According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, NVDA shares are trading higher by 1.67% to $162.66 Wednesday morning. The stock has a 52-week high of $164.42 and a 52-week low of $86.63.
Read Also: <a href="https://www.benzinga.com/markets/tech/25/07/46315651/nvidia-broadcom-avgo-stock-ai">Nvidia Is The Star―But Broadcom Is The AI Boom&#8217;s Best-Kept Secret</a>
<h2 class="wp-block-heading">How To Buy NVDA Stock</h2>
By now you're likely curious about how to participate in the market for NVIDIA &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of NVIDIA, which is trading at $162.66 as of publishing time, $100 would buy you 0.61 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
Image: Shutterstock

NVDA

Nvidia Hits $4 Trillion Market Cap, Stock Surges To All-Time High

Penny Stocks

Press Releases

CRGX Investors Have Opportunity to Join CARGO Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CARGO Therapeutics, Inc - CRGX

Biotech

General

CARGO Therapeutics Provides Corporate Update

CARGO Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $4.379 in Cash per Share Plus a Contingent Value Right

CRGX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of CARGO Therapeutics, Inc. Is Fair to Shareholders

Shareholder Alert: The Ademi Firm investigates whether CARGO Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CRGX, PBBK, COOP on Behalf of Shareholders

CARGO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CARGO Therapeutics, Inc. - CRGX

Comments

Cargo Therapeutics

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL